http://www.nccn.org The National Comprehensive Cancer Network (NCCN), an alliance of 21 of the world's leading cancer centers, is an authoritative source of comprehensive cancer care information that strives to insure the quality of cancer care and advance clinical research. Through the collaborative expertise of its member institutions, the NCCN develops, evaluates, and disseminates practice guidelines to support health professionals and patients in making informed treatment decisions. en-us Copyright 2008 NCCN Thu, 2 Sep 2010 00:00 GMT Thu, 2 Sep 2010 00:00 GMT http://www.nccn.org/images/nccn_logo.gif http://www.nccn.org 60 http://www.nccn.org/about/news/newsinfo.asp?NewsID=255 NCCN recently received two individual $2 million research grants from GlaxoSmithKline to evaluate the effectiveness of ofatumumab in hematologic malignancies and pazopanib in the treatment of solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding. July 27, 2010 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical studies of ofa... Tue, 27 Jul 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=254 Collaboration Integrates Evidence-Based Medicine and Innovative Decision Support Technologies, Providing Clinicians Access to the NCCN Guidelines at the Point of Care Fort Washington, Penn. and Newton, Mass., July 26, 2010 - The National Comprehensive Cancer Network® (NCCN®) and Proventys, a leader in advanced decision support technologies, have entered into an exclusive collaboration to introduce the Proventys CDS Oncology™ system, a first-of-its-kind Web platform that arms oncologists wit... Mon, 26 Jul 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=253 The National Comprehensive Cancer Network® (NCCN®) goes mobile with the launch of free NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) apps for iPhone and Android. These apps provide registered users of NCCN.org mobile access to the NCCN Guidelines™. June 16, 2010 FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) improves access to the latest information on cancer treatment recommendations with the launch of the NCCN Guidelines App for iPhone and And... Wed, 16 Jun 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=252 Identifying clinical trial benchmarking metrics and best practices at NCCN Member Institutions is the focus of a recent survey conducted by the National Comprehensive Cancer Network® (NCCN®). A poster presentation of the survey analysis will be featured at the 2010 ASCO Annual Meeting on June 7, 2010. June 4, 2010 FORT WASHINGTON - Clinical research is at the heart of National Comprehensive Cancer Network® (NCCN®) center operations, as it constitutes a core mission of NCCN Member Instituti... Fri, 4 Jun 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=251 Thomas A. D'Amico, MD, of the Duke Comprehensive Cancer Center, is the new chairman of the NCCN Board of Directors succeeding Al B. Benson III, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 1, 2010 FORT WASHINGTON, PA - Thomas A. D'Amico, MD, of the Duke Comprehensive Cancer Center has been elected to the position of chairman of the National Comprehensive Cancer Network® (NCCN®) Board of Directors. Dr. D'Amico was previously vice-chairman of the board... Thu, 1 Apr 2010 00:00 GMT http://www.roswellpark.org/media/audio/dr-mohler-presents-expert-testimony-prostate-cancer-federal-hearing ... Thu, 25 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=249 The international presence of the National Comprehensive Cancer Network® (NCCN®) continues to flourish with a busy spring schedule of programs in China designed to allow Chinese and other Asian experts ample opportunity to share and exchange experiences with their counterparts in the United States. March 24, 2010 FORT WASHINGTON, PA - Among recent reports that cancer diagnoses and deaths continue to decline in the United States, the same cannot be said about developing countries such as Ch... Wed, 24 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=248 Noting concern of the over-treatment and over-diagnosis of prostate cancer, James L. Mohler, MD, of Roswell Park Cancer Institute recently presented the updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Prostate Cancer at the National Comprehensive Cancer Center® (NCCN®) 15th Annual Conference. March 17, 2010 HOLLYWOOD, FL - Active surveillance, also referred to as watchful waiting, is a viable option for many men with low risk prostate cancer although the concep... Wed, 17 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=247 The National Comprehensive Cancer Network® (NCCN®) recently announced that select NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™), the most widely used guidelines in oncology practice around the globe, are being translated into Japanese. FORT WASHINGTON, PA - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) have been further recognized as the global standard in oncology with the announcement that select NCCN Guidelines™ are being translated i... Tue, 16 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=246 The lack of progress in treating the adolescent and young adult (AYA) population with cancer was the focus of a recent presentation at the National Comprehensive Cancer Network®'s (NCCN®'s) 15th Annual Conference. Decreased participation in clinical trials, biological differences, limited resources, and variations in care were highlighted as contributing factors to the disappointing outcomes. HOLLYWOOD, FL - Despite cancer survival rates increasing dramatically for children and older adul... Mon, 15 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=244 A roundtable led by Clifford Goodman, PhD, at the National Comprehensive Cancer Network® (NCCN®) 15th Annual Conference, presented various views on 'Clinical and Economic Issues Impacting Cancer Care Delivery.' The panel of experts tackled the spectrum of issues related to the use of evidence-based practice guidelines and the costs of cancer care. March 13, 2010 HOLLYWOOD, FL - The escalating costs of cancer care combined with variations in concordance with evidence-based practice guidelin... Sat, 13 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=245 NCCN® recently announced a new addition to the NCCN Guidelines™, the NCCN Guidelines for Malignant Pleural Mesothelioma. Lee M. Krug, MD, presented the recommendations that incorporate treatment options for patients with the rare form of cancer. March 13, 2010 HOLLYWOOD, FL - A new addition to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™), the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM), was presented at the NCCN 15th Annual Conference. Lee M. Krug, MD o... Sat, 13 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=242 Updates to the most recent version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Acute Myeloid Leukemia were presented at the NCCN 15th Annual Conference by B. Douglas Smith, MD of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Smith focused on cytogenetics and molecular markers, efforts to better define APL prognosis, and treatment options for elderly patients with AML. March 12, 2010 HOLLYWOOD, FL - Using risk stratification to assist in... Fri, 12 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=243 A roundtable dedicated to cancer care at the end of life presented at the NCCN 15th Annual Conference highlighted the need for personalized care, honesty, and maintaining hope. Sam Donaldson of ABC News moderated the emotional discussion between notable cancer survivors, family members, managed care representatives, and clinicians. March 12, 2010 HOLLYWOOD, FL - Despite the advances and groundbreaking research being performed in the area of cancer treatment, sometimes cancer cannot be cure... Fri, 12 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=240 Highlights of the latest version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Colon and Rectal Cancer were presented at the NCCN 15th Annual Conference by Paul F. Engstrom, MD, of Fox Chase Cancer Center. Engstrom discussed specific recommendations for therapies and provided guidance on patients who benefit most from select regimens. March 11, 2010 HOLLYWOOD, FL - Despite statistics stating that colorectal cancer is the fourth most frequently diagnosed cancer... Thu, 11 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=241 HPV infection can increase the risk of developing cervical cancer as well as anal carcinoma and head and neck cancers according to physicians from National Comprehensive Cancer Network® (NCCN®) Member Institutions. The role of the HPV vaccine as well as prevention strategies were discussed during a recent presentation at the NCCN 15th Annual Conference. March 11, 2010 HOLLYWOOD, FL - The Human Papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer, but is... Thu, 11 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=239 The National Comprehensive Cancer Network® (NCCN®) announces that veteran newsman Sam Donaldson has accepted the position of chair of the NCCN Foundation Board of Directors. The NCCN Foundation will seek philanthropic support for programs to benefit patients with cancer as well as researchers. March 10, 2010 HOLLYWOOD, FL - The NCCN 15th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ commenced on Wednesday, March 10, 2010 with an announcement that veteran ABC ne... Wed, 10 Mar 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=238 The National Comprehensive Cancer Network (NCCN®) introduces NCCN Flash Updates™, a new service that provides notification when an update is made to the NCCN Guidelines™ or NCCN Compendium™. A preview of an NCCN Flash Update was recently sent to all registered users of NCCN.org notifying them that the NCCN Guidelines™ for Malignant Pleural Mesothelioma (MPM) was published as an addition to the Complete Library of NCCN Guidelines™. February 1, 2010 FORT WASHINGTON, PA - The National Compreh... Mon, 1 Feb 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=237 The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Ovarian Cancer to include two additional combination treatment regimens for women with select types of recurring ovarian cancer. January 25, 2010 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients bas... Mon, 25 Jan 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=236 The National Comprehensive Cancer Network (NCCN) announces the NCCN REMS Oncology Summit scheduled for May 2010 to discuss recommendations for the appropriate application of Risk Evaluation and Mitigation Strategies (REMS) in cancer care. January 12, 2010 FORT WASHINGTON, PA - Risk evaluation and mitigation strategies (REMS), which can be required by the FDA for drugs or biologics with significant toxicity and/or risks, are emerging as a priority topic for a variety of individuals. The goa... Tue, 12 Jan 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=235 The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Prostate Cancer to include new recommendations for men who should consider active surveillance, as well as a new 'very low risk' category. January 7, 2010 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Prostate Cancer to reflect new recommendations regarding active surveillance, also referred to as watchfu... Thu, 7 Jan 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=234 NCCN updates the NCCN Guidelines for Non-Small Cell Lung Cancer to include guidance on maintenance therapy, several new therapeutic recommendations for specific patients with Non-Small Cell Lung Cancer, and a revised staging system. December 9, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) to incorporate a new section about maintenance therapy, a number of new indications for specific ... Wed, 9 Dec 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=233 Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra™, GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax®, Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL). November 23, 2009 FORT WASHINGTON, PA - Two recent FDA approvals have prompted the National Comprehensive Cance... Mon, 23 Nov 2009 00:00 GMT \about\news\pdf\Discovery_Health_Breast-2009-11-20.pdf ... Fri, 20 Nov 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=231 New Informational Resource: NCCN Risk-Based Breast Cancer Screening Guidelines (Webcast) This activity is not approved for CME/CE credits. November 16, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines in Oncology™ for Breast Cancer Screening and Diagnosis and continues to recommend annual clinical breast examinations and mammography for women 40 years and older at normal risk. 'For women age 40 and over, the be... Mon, 16 Nov 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=230 NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. November 10, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) h... Tue, 10 Nov 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=229 The National Comprehensive Cancer Network (NCCN) has posted a draft white paper for public comment that details a draft paradigm for near-term comparative effectiveness clinical evaluations based upon existing data. The document introduces the NCCN Comparative Therapeutic Index™ (CTI), a consensus-based process that compares the risk-versus-benefit of different treatment options recommended in the NCCN Clinical Practice Guidelines in Oncology™. The paper will be posted for public comment throu... Mon, 9 Nov 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=228 The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma. In conjunction with this update, NCCN presents a series of free webinars scheduled for the week of November 9, 2009, hosted by an NCCN Guidelines Panel Member to review the information that supported modification of the NCCN Guidelines. November 3, 2009 FORT WASHINGTON, PA - Following the recent FDA approval of... Tue, 3 Nov 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=227 Although colonoscopy remains the preferred colorectal cancer screening method, the recently updated NCCN Guidelines for Colorectal Cancer Screening have added annual immunohistochemical stool testing with or without a flexible sigmoidoscopy every five years as an alternate screening option for average risk individuals. Additional updates include guidelines for individuals with three rare syndromes putting them at greater risk for developing the disease. November 2, 2009 FORT WASHINGTON, PA... Mon, 2 Nov 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=226 The removal of a noncancerous breast (prophylactic mastectomy) is generally discouraged in women other than those at high risk as stated in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ for Breast Cancer. Other noteworthy updates to the NCCN Guidelines include a new regimen for adjuvant chemotherapy in invasive breast cancer and the option for women with clinically negative lymph nodes to avoid a full axillary lymph node dissection. Octob... Wed, 28 Oct 2009 00:00 GMT /about/news/pdf/NCCN-unitedhealthcare-release.pdf ... Thu, 22 Oct 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=224 The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Acute Myeloid Leukemia (AML), the most common acute leukemia affecting adults. Noteworthy updates include the incorporation of risk stratification based on white blood cell count, the alternative to use cord blood in allogeneic stem cell transplants, and new treatment options for adults over the age of 60 with AML. October 16, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN)... Mon, 19 Oct 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=223 NCCN program on Discovery Health Channel profiles patients battling advanced non-small cell lung cancer and highlights their physicians' use of the NCCN Guidelines for Non-Small Cell Lung Cancer in determining the best treatment regimen. The program, which provides free CME credits, premieres on Sunday, October 18 at 7:00 AM EDT. October 16, 2009 FORT WASHINGTON, PA - Lung cancer is the second most common cancer and leading cause of cancer-related deaths in both men and women. Although tob... Fri, 16 Oct 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=222 NCCN has added pralatrexate (Folotyn™, Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma. The FDA approved pralatrexate for the treatment of peripheral T-cell lymphoma on September 25, 2009. October 15, 2009 FORT WASHINGTON, PA - Upon the recent FDA approval of pralatrexate (Folotyn™, Allos Therapeutics, Inc.) for the treatment of relapsed or refractory peripheral ... Thu, 15 Oct 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=221 The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Cervical Cancer Screening to provide further recommendations for a subset of women with conflicting results on cervical cytology/Pap tests and Human papillomavirus (HPV) High Risk DNA tests. The NCCN Guidelines include recommendations regarding screening techniques, screening intervals, and management of abnormal screening resulting from cervical cytology/Pap smear and colposcopy. October 14, 2009 FOR... Wed, 14 Oct 2009 00:00 GMT /about/news/pdf/NCCN-CCO-release.pdf ... Wed, 23 Sep 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=219 NCCN is holding the NCCN Oncology Research Best Practices Conference™, an interactive forum to discuss the regulatory and operational aspects of research and help identify areas in the clinical trial process where improvements can be made. Scheduled for October 26 - 27 in Bethesda, MD, the conference will include lectures, interactive workshops, and panel discussions on topics that challenge the conduct of oncology research as well as topics related to ethical considerations. September 14, ... Mon, 14 Sep 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=218 The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Prostate Cancer Early Detection incorporating the results of the recent ERSPC trial that assessed the benefit of PSA screening. The NCCN Guidelines contend that PSA screening does save lives when performed intelligently in men at high-risk of developing the disease. August 10, 2009 FORT WASHINGTON, PA - Prostate-Specific Antigen (PSA) testing performs optimally when conducted intelligently and combine... Mon, 10 Aug 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=217 NCCN recently updated the NCCN Clinical Practice Guidelines in Oncology™ for the Prevention and Treatment of Cancer-Related Infections to include information about the H1N1 virus, also known as 'swine flu'. The NCCN Guidelines provide specific recommendations on the prevention, diagnosis, and treatment of the major common and opportunistic infections that afflict patients with cancer. August 5, 2009 FORT WASHINGTON, PA - Infectious diseases are important causes of morbidity and mortality i... Wed, 5 Aug 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=216 The National Comprehensive Cancer Network (NCCN) is developing a methodology for the evaluation and application of the Comparative Effectiveness of health care technologies in cancer care. This work will culminate with the NCCN National Policy Summit on Comparative Effectiveness in Cancer Care to be held in December 2009. July 22, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) is an alliance of 21 of the world's leading cancer centers dedicated to improving the... Wed, 22 Jul 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=215 NCCN announces open registration for a west coast session of NCCN Academy for Excellence & Leadership in Oncology™ School of Pharmaceutical & Biotech Business scheduled for July 9 - 10, 2009 in San Francisco. This new educational offering is designed to give pharmaceutical and biotech professionals the rare opportunity to view the oncology space and its current and future operational issues from the provider and payer perspective. June 8, 2009 FORT WASHINGTON, PA - Industry profess... Mon, 8 Jun 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=214 A pilot study of a new productivity tool developed by the National Comprehensive Cancer Network (NCCN) shows potential in measuring the impact of mid-level oncology providers in outpatient oncology settings. Refining productivity metrics for this group can help inform workforce projections given reports of a looming shortage of oncologists. The results will be presented at the ASCO Annual Meeting on May 30, 2009 in Orlando, Florida. ORLANDO, FL - Mid-level providers have the potential to mi... Mon, 1 Jun 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=213 NCCN recently updated the NCCN Guidelines for Venous Thromboembolic Disease, which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE), and is a common condition in people with cancer. Noted updates include the expanded use of graduated compression stockings in prophylaxis and treatment, and a strengthened recommendation for VTE prophylaxis in general. May 20, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) announces new updates to the NCCN Cl... Wed, 20 May 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=212 NCCN recently updated the NCCN Guidelines for Central Nervous System (CNS) Cancers. Important new updates include the recommendation to use bevacizumab as a single agent for recurrent glioblastoma multiforme in CNS cancers, the integration of a patient's Karnofsky Performance Status (KPS) score into treatment decisions, and an adjusted age range for adjuvant therapy options in patients with low grade gliomas. May 18, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCC... Mon, 18 May 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=211 The NCCN Oncology Research Program (ORP) nears the $20 million mark in total funding and enhances its current model to include funding for therapeutics in development as well as those already FDA-approved. The ORP draws on the expertise of investigators at 21 of the world's leading cancer centers (NCCN Member Institutions) in order to advance therapeutic options for patients with cancer. April 29, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) Oncology Research... Wed, 29 Apr 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=210 NCCN has added everolimus (Afinitor®, Novartis) to the NCCN Guidelines for Kidney Cancer as a recommended treatment for patients with renal cell carcinoma whose disease has progressed after treatment with kinase inhibitors. This recommendation comes on the heels of the March 30, 2009 FDA approval of everolimus based upon results of a clinical trial which showed that the therapy significantly extended progression-free survival in a specific group of patients. April 20, 2009 FORT WASHINGTON,... Mon, 20 Apr 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=207 A roundtable led by Clifford Goodman, PhD, at the NCCN 14th Annual Conference, presented various views on 'Finding and Achieving Value in Cancer Care.' The panel of experts tackled the spectrum of issues related to defining value, and the concern that the benefit to patients of some of the latest cancer treatments may not warrant their costs. March 16, 2009 HOLLYWOOD, FL - Oncology is an area of rapid growth, both in terms of technological innovation and costs in cancer care and treatment.... Mon, 16 Mar 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=208 New updates to the NCCN Clinical Practice Guidelines in Oncology™ for Ovarian Cancer were presented at the NCCN 14th Annual Conference on March 14. Notable additions to the NCCN Guidelines are a section on managing allergic reactions to chemotherapy agents and new agents for recurrence therapy. Robert J. Morgan, MD, of City of Hope Comprehensive Cancer Center presented the updated NCCN Guidelines that continue to stress early detection of ovarian cancer and the enrollment of patients in clinic... Mon, 16 Mar 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=209 NCCN presented new updates to the NCCN Clinical Practice Guidelines in Oncology™ for Thyroid Carcinoma at the NCCN 14th Annual Conference on March 14. Notable updates include a new page on Thyroid Stimulating Hormone (TSH) Suppression, the expanded recommendation of small molecule kinase inhibitors, and revised procedures for evaluating thyroid nodules. Steven I. Sherman, MD, of The University of Texas M. D. Anderson Cancer Center and chair of the NCCN Guidelines Panel for Thyroid Carcinoma, p... Mon, 16 Mar 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=206 NCCN presented new NCCN Clinical Practice Guidelines in Oncology™ for Primary Cutaneous B-Cell Lymphoma as well as important updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas at the NCCN 14th Annual Conference. The new NCCN Guidelines were written to distinguish Primary B-Cell Lymphomas from their nodal counterparts and provide clinicians with treatment recommendations. Andrew D. Zelenetz, MD, PhD, and Steven M. Horowitz, MD, both of Memorial Sloan-Kettering Cancer Center, presented t... Sat, 14 Mar 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=204 Minimally-invasive oncologic surgery procedures can be beneficial, but physicians need to be prudent when recommending the option to their patient according to Thomas A. D'Amico, MD, of Duke Comprehensive Cancer Center. Dr. D'Amico detailed the benefits and controversies of minimally invasive alternatives as well as emerging techniques including natural orifice surgery at the NCCN 14th Annual Conference. March 13, 2009 HOLLYWOOD, FL - Cutting-edge surgery with less cutting is appealing for... Fri, 13 Mar 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=205 New updates to the NCCN Guidelines for Pancreatic Adenocarcinoma were announced on March 12 at the NCCN 14th Annual Conference. Notable additions include updates on when a laparoscopy may be beneficial to patients, clarification on diagnostic imaging protocols, and an overall emphasis on systemic therapy in all disease stages. Pancreatic adenocarcinoma is the second most common cause of death from gastrointestinal cancer. March 13, 2009 HOLLYWOOD, FL - The National Comprehensive Cancer Net... Fri, 13 Mar 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=203 A roundtable dedicated to cancer survivorship at the NCCN 14th Annual Conference highlighted the need for transition care plans and improved physician/patient communication for cancer survivors. Sam Donaldson of ABC News moderated the lively discussion between cancer advocates, survivors, and clinicians that touched upon the host of issues cancer survivors face upon the completion of treatment. The NCCN Annual Conference has achieved record attendance this year with more than 1600 registered a... Thu, 12 Mar 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=202 NCCN announces new modifications to the NCCN Guidelines for Colon and Rectal Cancers. Important additions include a new survivorship section, new indications for cetuximab as it relates to KRAS gene testing, and recommendations on how to re-evaluate patients initially presenting with unresectable disease. Colorectal cancer remains the third most frequently diagnosed cancer in men and women in the United States. February 18, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Netwo... Wed, 18 Feb 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=201 FORT WASHINGTON, PA - JNCCN - The Journal of the National Comprehensive Cancer Network announces the appointment of a new publishing company, Cold Spring Publishing, LLC. This appointment reflects the growth and depth of JNCCN, a peer-reviewed, indexed medical journal that provides the latest information about best clinical practices, oncology outcomes, and new research initiatives. Cold Spring Publishing is a newly formed medical publishing company based in Huntington, New York. Jack Gentile, ... Tue, 10 Feb 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=200 NCCN announces new updates to the NCCN Guidelines for Breast Cancer and Breast Cancer Risk Reduction Guidelines. Noteworthy additions include new recommendations on when to use MRIs in breast cancer evaluations, statements discouraging the use of PET/CT scanning for evaluative purposes, and new cosmetic recommendations for women undergoing reconstructive surgery. February 3, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCC... Tue, 3 Feb 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=199 NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC). This grant is the largest research award received by NCCN to date. Investigators from NCCN Member Institutions are eligible to apply for the research funding. January 15, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Networ... Thu, 15 Jan 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=198 NCCN, in collaboration with the Abu Dhabi Health Services Company (SEHA), announce The Second Annual Middle East and North Africa NCCN Guidelines Congress scheduled for April 23 – 26, 2009 in Abu Dhabi, United Arab Emirates (UAE). The program will present the latest developments in treating common cancers and generate discussions around developing regional guidelines. January 14, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN) is pleased to announce that it... Wed, 14 Jan 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=197 A record number of individuals participated in the first NCCN Oncology Case Management Program to be held in Philadelphia on December 11and12, 2008. The training program, which is offered at no cost to participants, provides case managers, medical directors, and clinical pharmacists with a comprehensive overview of important issues in cancer care. December 16, 2008 FORT WASHINGTON, PA — With the recent news that cancer is expected to be the world’s new leading cause of death by 2010, ... Tue, 16 Dec 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=196 NCCN has been awarded a $1M research grant from MerckandCo, Inc., that will support research of the anti-cancer agent vorinostat (Zolinza). Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the efficacy of vorinostat in combination with chemotherapy and/or radiation therapy in selected locally advanced non-metastatic cancers including non-small cell lung cancer, head and neck cancer, pancreati... Mon, 1 Dec 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=195 NCCN has been awarded a $1.5 Million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research on the antibody cetuximab in patients with bladder cancer. The novel targeted therapy has proven effective in various other types of cancer including colorectal and head and neck. The University of Michigan Comprehensive Cancer Center is the coordinating center for the study. November 24, 2008 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN... Mon, 24 Nov 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=194 NCCN announces new updates to the NCCN Guidelines for Colon and Rectal Cancers. The updates include recommendations to the pre-treatment work-up and use of anti-cancer agents in patients with metastatic colorectal cancer depending on the status of the tumor’s KRAS gene. The changes are based on recent studies demonstrating that the tumor KRAS gene status is highly predictive of outcome with certain therapies. November 03, 2008 FORT WASHINGTON, PA — The National Comprehensive Cancer Ne... Mon, 3 Nov 2008 00:00 GMT http://www.nccn.org/about/news/pdf/AO990-266534.pdf ... Tue, 7 Oct 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=192 FORT WASHINGTON, Pa., September 10, 2008 — The National Comprehensive Cancer Network, (NCCN), announces important updates to the NCCN DrugsandBiologics Compendium Non-Small Cell Lung Cancer. The following changes relate to use in the treatment of Non-Small Cell Lung Cancer and are as follows: Cetuximab (Erbitux, Bristol-Myers Squibb/ImClone Systems Incorporated) - First-line therapy for recurrence or metastasis in combination with vinorelbine and cisplatin for performance status 0-2 patients ... Wed, 10 Sep 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=191 FORT WASHINGTON, Pa., July 10, 2008 — The Journal of the National Comprehensive Cancer Network (JNCCN) has named Harold J. Burstein, MD, PhD, as its new editor-in-chief. Dr. Burstein will lead and set the direction of the journal as well as serve as the ambassador for JNCCN in the oncology community. Dr. Burstein is a medical oncologist specializing in the treatment of breast cancer at the Dana-Farber Cancer Institute in Boston and an Associate Professor of Medicine at Harvard Medical School. A... Thu, 10 Jul 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=157 NCCN is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) has recognized the NCCN DrugsandBiologics Compendium as a mandated reference for establishment of coverage policy and coverage decisions regarding the use of drugs and biologics in cancer care. The NCCN Compendium will be used by CMS for national coverage determinations and by intermediaries and carriers for locoregional determinations. The major application will be in determinations about coverage for the us... Thu, 5 Jun 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=138 FORT WASHINGTON, Pa., June 4, 2008 — The National Comprehensive Cancer Network (NCCN), an alliance of 21 of the world’s leading cancer centers, will expand its current disclosure process and make public all potential conflicts of interest of all individual expert panel members by the end of 2008. This information will begin to appear online at www.nccn.org in July. The NCCN began to expand its disclosure procedures for its NCCN Drugs and Biologics Compendium and its NCCN Clinical Practice Guid... Wed, 4 Jun 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=137 FORT WASHINGTON, Pa., May 30, 2008 — An initial set of NCCN Chemotherapy Order Templates, peer-reviewed and evidence-based chemotherapy regimens with indications, doses, and schedules and routes of administration will be previewed at the upcoming American Society of Clinical Oncology (ASCO) meeting to be held May 31 to June 2, 2008. The Templates can enhance patient safety by helping clinicians standardize patient care, reduce medication errors and anticipate and manage adverse events. They ... Fri, 30 May 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=190 Chemotherapy templates developed by the NCCN to be included in Zynx OncologyCare Los Angeles, CA and Fort Washington, PA – May 30, 2008 – Zynx Health, the leader in evidence-based healthcare, today announced it will partner with the National Comprehensive Cancer Network (NCCN) to make NCCN chemotherapy templates available to users of the new Zynx OncologyCare product. An alliance of 21 of the nation’s leading cancer centers, the NCCN is an authoritative source of information to help patie... Tue, 20 May 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=136 FORT WASHINGTON, Pa., April 22, 2008 — The National Comprehensive Cancer Network (NCCN) announces several new updates to the NCCN Clinical Practice Guidelines in Oncology Non-Hodgkin’s Lymphoma (NHL). These changes highlight leading developments in the treatment of NHL and represent the recognized standard for clinical care in oncology in both the community and the academic practice settings. The NHL Guidelines now include bendamustine (Treanda, Cephalon) as a treatment option for chronic lymph... Tue, 22 Apr 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=189 For Immediate Release April 3, 2008 Deborah Pettibone (716) 845-8593 Deborah.pettibone@roswellpark.org Roswell Park Opens One of Nation’s First Oncology-Specific Clinical Research Centers BUFFALO, NY – Roswell Park Cancer Institute (RPCI) officially opened its $2.6 million Clinical Research Center today, dedicating the facility to the development of new cancer therapies while providing more treatment options for patients through clinical trials. The Center is one of only a few clini... Thu, 3 Apr 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=134 HOLLYWOOD, Fla., March 27, 2008 —Americans older than 65 years are expected to double from 40 million in 2010 to 80 million in 2040. This will lead to a large increase in breast cancer among American women, the leader of a task force reported during the National Comprehensive Cancer Network’s 13th Annual Conference. But is the medical community ready? Stanford oncologist and Professor Robert W. Carlson, M.D., who chairs NCCN’s task force on breast cancer in the older adult, says many questio... Thu, 27 Mar 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=135 HOLLYWOOD, Fla., March 27, 2008 — The 21st century will be a time of personalized care for patients with breast cancer where tools such as biomarkers, multi-gene assays and single-gene assays will help clinicians individualize treatment, according to Peter Ravdin, M.D., Ph.D presenting at the NCCN 13th Annual Conference. However, he cautioned, further validation is still necessary to confirm some of the predictive capacities of these tests. Dr. Ravdin, a research professor in biostatistics at ... Thu, 27 Mar 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=132 FORT WASHINGTON, Pa., March 13, 2008 — This week, the Blue Cross and Blue Shield Association (BCBSA) announced that the National Comprehensive Cancer Network (NCCN) is a strategic collaborator in oncology. For the last 23 months, the two organizations have worked together to develop Blue Distinction Centers for Complex and Rare CancersSM, a designation that focuses on multidisciplinary treatment planning and complex, major surgical treatments for 13 specific types of cancer. Blue Distinction C... Thu, 13 Mar 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=133 HOLLYWOOD, Fla., March 13, 2008 — Several recently approved agents offer promising treatment possibilities for patients with metastatic renal cell carcinoma (RCC) and the order in which these agents are administered may positively impact clinical response, according to a presentation given during the National Comprehensive Cancer Network (NCCN) 13th Annual Conference: Clinical Practice GuidelinesandQuality Cancer Care. Until recently, there were very few agents to treat RCC and those available ... Thu, 13 Mar 2008 00:00 GMT http://www.nccn.org/about/publications/pdf/080311_Complex_And_Rare_Cancers.pdf ... Thu, 13 Mar 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=131 HOLLYWOOD, Fla., March 7, 2008 — Cancer’s two most compelling words these days are “cure” and “costs,” and each holds capacity to create patient heartache and promise, according to roundtable participants at the National Comprehensive Cancer Network’s 13th Annual Conference, March 5-9. When doctors recommend cancer treatments, best practices dictate that they follow guidelines created by NCCN and other professional medical organizations. Currently, such guidelines do not include treatment-co... Fri, 7 Mar 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=130 HOLLYWOOD, Fla., March 6, 2008 — Soon the Internet may hold your medical record where you and your doctor can access it at all hours. Even if you are undergoing a complicated chemotherapy regimen, your computer may prompt you to follow doctor’s orders and, via a daily questionnaire, alert your doctor to any new problems, predicted roundtable participants at the National Comprehensive Cancer Network’s 13th Annual Conference, March 5-9. Former AOL chief Steve Case said he launched RevolutionHea... Thu, 6 Mar 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=129 FORT WASHINGTON, Pa., March 4, 2008 — The National Comprehensive Cancer Network (NCCN) announced today its collaboration with Cerner Corporation (NASDAQ:CERN) to provide evidence-based care guidelines for patients with cancer to healthcare organizations utilizing the Cerner Millennium healthcare computing platform. “These efforts represent a continuing collaboration to integrate Cerner’s significant capabilities in electronic medical records with NCCN’s multidisciplinary expertise in oncology ... Tue, 4 Mar 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=128 FORT WASHINGTON, Pa., February 26, 2008 — The National Comprehensive Cancer Network (NCCN) is pleased to announce several new updates to the NCCN Clinical Practice Guidelines in Oncology™ Ovarian Cancer. These changes highlight leading developments in the treatment of ovarian cancer and represent the recognized standard for clinical care in oncology in both the community and the academic practice settings. Patients with ovarian cancer were once thought to exhibit no symptoms during the early st... Tue, 26 Feb 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=127 FORT WASHINGTON, Pa., January 22, 2008 — The National Comprehensive Cancer Network (NCCN) is proud to announce several new updates to the NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer. These changes highlight leading developments in the treatment of breast cancer and represent the recognized standard for clinical care in oncology in both the community and the academic practice settings. A new section focusing on the treatment of patients with inflammatory breast cancer (IBC) has ... Tue, 22 Jan 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=187 Media Contact: Dagny Stuart Information Officer Vanderbilt-Ingram Cancer Center 615-936-7245 dagny.stuart@vanderbilt.edu January 17, 2008 Pietenpol Chosen to Lead Vanderbilt-Ingram Cancer Center Nashville, Tenn. - Jennifer Pietenpol, Ph.D., Ingram Professor of Cancer Research and professor of Biochemistry, has been named director of Vanderbilt-Ingram Cancer Center. Pietenpol became interim director last February and quickly emerged as a strong and respected leader with the righ... Thu, 17 Jan 2008 00:00 GMT http://www.nccn.org/about/publications/pdf/NCCN_United_Healthcare_Announcement.pdf ... Wed, 16 Jan 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=126 FORT WASHINGTON, Pa., January 11, 2008 — Articles from JNCCN – The Journal of the National Comprehensive Cancer Network, a peer-reviewed medical journal covering the entire spectrum of oncologic health care, are now available on Medscape. Articles cover a variety of topics in oncology, including adjuvant therapy for colon cancer, the STAR Trial and active surveillance for favorable-risk prostate cancer. These articles, originally published in JNCCN and distributed only to its readers, are avai... Fri, 11 Jan 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=125 FORT WASHINGTON, Pa., December 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the use of erythropoietin-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa. ESAs are no longer recommended for the treatment of cancer-related anemia associated with solid tumors or hematologic malignancies other than myelodysplastic syndromes (MDS). ESA therapy is an option for patient... Thu, 20 Dec 2007 00:00 GMT http://www.jsonline.com/story/index.aspx?id=691779 ... Sun, 2 Dec 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=124 JENKINTOWN, Pa., November 26, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Pancreatic Adenocarcinoma Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. These NCCN Guidelines feature a new section covering principles of palliation and supportive care. This is an especially important addi... Mon, 26 Nov 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=123 JENKINTOWN, Pa., November 15, 2007 — The National Comprehensive Cancer Network (NCCN), ImClone Systems Incorporated and Bristol-Myers Squibb have entered into a collaboration to conduct a multi-institutional, investigator-initiated study in head and neck cancer using cetuximab. Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania is the coordinating center for this study, with Corey Langer, M.D., serving as Project Chairman. Cetuximab, also known by its brand name ERBITUX, is currentl... Thu, 15 Nov 2007 00:00 GMT http://www.siteman.wustl.edu/internal.aspx?id=2390 ... Thu, 1 Nov 2007 00:00 GMT http://www.nccn.org/about/publications/pdf/kLeeGrant102907.pdf ... Wed, 31 Oct 2007 00:00 GMT http://www.nccn.org/about/publications/pdf/ASTRO_TMI_final.pdf ... Mon, 29 Oct 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=119 JENKINTOWN, Pa., October 23, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Central Nervous System (CNS) Cancers Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. The NCCN CNS panel revised the guidelines by providing radiation therapy dosing and new detailed recommendations for chemot... Tue, 23 Oct 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=120 JENKINTOWN, Pa., October 23, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Multiple Myeloma Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. The NCCN Multiple Myeloma Guidelines now include bortezomib (Velcade, Millennium Pharmaceuticals)in combination with pegylated liposomal doxorubi... Tue, 23 Oct 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=121 JENKINTOWN, Pa., October 23, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. An entirely new section has been added to the NSCLC guidelines for Thymic Malignancies, which include thymomas and thymic carci... Tue, 23 Oct 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=122 JENKINTOWN, Pa., October 22, 2007 — JNCCN – The Journal of the National Comprehensive Cancer Network, a peer-reviewed medical journal covering the entire spectrum of oncologic health care, will now be used by the Centers for MedicareandMedicaid Services (CMS) and by its carriers and intermediaries as a mandated reference for off-label use of anti-cancer drugs. Many common cancer treatments are administered off-label, and evidence for such administration is often found in peer-reviewed medical ... Mon, 22 Oct 2007 00:00 GMT http://www.hopkinskimmelcancercenter.org/news/index.cfm?documentid=931&newstype=News%20Releases&action=showthisitem ... Thu, 11 Oct 2007 00:00 GMT http://www.jamesline.com/news/press/?ID=3483&0&SIDS ... Mon, 8 Oct 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=116 JENKINTOWN, Pa., September 11, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Dermatofibrosarcoma Protuberans (DFSP) Guidelines. DFSP is a rare, low-grade sarcoma characterized by a t(17;22) chromosomal translocation resulting in the over-expression of platelet-derived growth factor receptor '(PDGFRB). This abnormal proliferation of cells can quickly grow into a malignant tumor. In a phase II open-label trial—Study B2225, the largest study invol... Tue, 11 Sep 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=117 JENKINTOWN, Pa., September 11, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Hepatobiliary Cancer Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. The guidelines now include sorafenib (Nexavar), an oral multikinase inhibitor, as a treatment option for patients with hepatocellular carci... Tue, 11 Sep 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=118 JENKINTOWN, Pa., September 11, 2007 — JNCCN —The Journal of the National Comprehensive Cancer Network, a peer-reviewed medical journal covering the entire spectrum of oncologic health care, now provides educational content on-line. Educational supplements, originally published as “NCCN Task Force Reports” in JNCCN and distributed only to its readers, are available for download at www.nccn.org/JNCCN/supplements.asp. NCCN regularly convenes groups of experts to discuss and expand on issues in t... Tue, 11 Sep 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=114 JENKINTOWN, Pa., August 1, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Kidney Cancer Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. The panel added temsirolimus (TORISEL, Wyeth) as an option in first-line therapy for patients with relapsed or medically unresectable stage IV renal c... Wed, 1 Aug 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=115 JENKINTOWN, Pa., August 1, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cervical Cancer Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. The cervical cancer guidelines have been updated to expand the indications for fertility-preserving surgery. Women with stage IB1 disease whose lesi... Wed, 1 Aug 2007 00:00 GMT http://www.nccn.org/about/publications/pdf/cancer_patients_lost_in_a_maze.pdf ... Sun, 29 Jul 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=113 JENKINTOWN, Pa., June 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Non-Hodgkin’s Lymphoma (NHL) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are updated continuously by panels of world-renowned experts and are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. The NHL Panel added new guidelines for peripheral T-Cell lymphomas, a group of ag... Tue, 19 Jun 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=112 JENKINTOWN, Pa., June 5, 2007 — The National Comprehensive Cancer Network (NCCN) will publish a special report entitled NCCN Task Force Report: Positron Emission Tomography (PET)/Computed Tomography (CT) Scanning in Cancer as a supplement to the May issue of its journal. The report is the work of a Task Force convened by NCCN to develop clinical recommendations for the use of PET and PET/CT in the evaluation and management of certain types of cancer. PET is a non-invasive imaging technique use... Tue, 5 Jun 2007 00:00 GMT http://www.fccc.edu/news/2007/Seiden-Office-06-01-07.html ... Fri, 1 Jun 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=111 JENKINTOWN, Pa., May 31, 2007 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Clinical Practice Guidelines in Oncology - Thyroid Carcinoma. The NCCN Guidelines are updated continuously by panels of world-renowned experts and are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. For papillary, follicular and Hürthle cell carcinoma, the NCCN Thyroid Carcinoma Panel revi... Thu, 31 May 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=109 JENKINTOWN, Pa., May 22, 2007 — The National Comprehensive Cancer Network (NCCN) announces updates to two NCCN Clinical Practice Guidelines in Oncology - Esophageal Cancer and Gastric Cancer. The NCCN Guidelines are updated continuously by panels of world-renowned experts and are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. In response to favorable Phase III trials (ML 17032 and REAL 2), the pa... Tue, 22 May 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=110 JENKINTOWN, Pa., May 22, 2007 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Clinical Practice Guidelines in Oncology - Head and Neck Cancers. The NCCN Guidelines are updated continuously by panels of world-renowned experts and are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. The NCCN Guidelines contain a newly modified risk categorization to assess whether pati... Tue, 22 May 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=175 Tampa, FL (May 16, 2007) – The H. Lee Moffitt Cancer CenterandResearch Institute has been awarded an $8.95 million grant from the National Cancer Institute. The long-term goal of research being conducted through the grant is the discovery of novel drugs for the treatment of cancer based on disrupting aberrant signal transductions circuits in human tumors. “At this time in history, a project of this caliber is considered a monumental accomplishment,” said Said Sebti, Ph.D., program leader of the... Wed, 16 May 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=107 JENKINTOWN, Pa., April 30, 2007 — The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology are developed and updated continually by multidisciplinary panels of expert physicians from NCCN Member Institutions. Reflecting this constant expansion and improvement, NCCN announces important updates to the NCCN Fever and Neutropenia Guidelines. The first change is that the guidelines have a new name: “Prevention and Treatment of Cancer-Related Infections.” Prior NCCN... Tue, 1 May 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=176 Vision for the Future of America’s First Cancer Center Offered BUFFALO, NY – The Board of Directors of the Roswell Park Cancer Institute Corporation (RPCIC) today introduced Donald L. Trump, MD,* as the new President and Chief Executive Officer of Roswell Park Cancer Institute (RPCI). He succeeds David C. Hohn, MD, who is credited with re-establishing the Institute as a leading cancer center during his 10-year administration. He stepped down March 31 to assume the roles of Executive Dire... Tue, 24 Apr 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=105 JENKINTOWN, Pa., April 11, 2007 —Al B. Benson III, M.D., has been elected to the position of Chairman of the Board of the National Comprehensive Cancer Network (NCCN). Thomas A. D’Amico, M.D., has been elected to the position of Vice-Chairman. Dr. Benson is the Associate Director for Clinical Investigations at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Professor of Medicine at Northwestern University’s Feinberg School of Medicine in Chicago, Illinois. Dr. Ben... Wed, 11 Apr 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=104 JENKINTOWN, Pa., March 22, 2007 — The National Comprehensive Cancer Network (NCCN), an alliance of the world’s leading cancer centers, is pleased to introduce a new NCCN Member Institution—Vanderbilt-Ingram Cancer Center (VICC) in Nashville, Tennessee. With this addition, NCCN now includes 21 centers dedicated to improving the quality, effectiveness and efficiency of oncology practice so patients can live better lives. Affiliated with Vanderbilt University and Medical Center, Vanderbilt-Ingram... Thu, 22 Mar 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=103 HOLLYWOOD, Fla., March 19, 2007 — Failure to recognize the role of stem cells in metastasis may have led cancer researchers up “blind alleys” in countless clinical trials, said Max S. Wicha, M.D., founding director and distinguished professor of internal medicine at the University of Michigan Comprehensive Cancer Center, speaking at the National Comprehensive Cancer Network’s 12th Annual Conference. With tumor shrinkage the primary guidepost of any new treatment, valuable therapies may be abort... Mon, 19 Mar 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=101 HOLLYWOOD, Fla., March 16, 2007 — With patients forced to pay a greater percentage out of pocket for high-priced therapies, some companies have abandoned promising anti-cancer drugs rather than devote hundreds of millions of dollars to complete all phases of a clinical trial, an industry analyst said at the National Comprehensive Cancer Network’s 12th Annual Conference, March 14-18. “There is a changing dynamic,” said Schumarry Chao, M.D., MBA, whose company advises CEOs on prescription drug pr... Fri, 16 Mar 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=102 HOLLYWOOD, Fla., March 16, 2007 — Even surgeons who once favored traditional “open” methods of cutting and suturing during prostate or bladder-cancer operations have learned to love the joystick-operated robot, said Timothy G. Wilson, M.D., director of the Prostate Cancer Program at City of Hope Cancer Center, at the National Comprehensive Cancer Network’s 12th Annual Conference, March 14-18. Studies show that men undergoing radical prostatectomy go home sooner and regain bladder control and s... Fri, 16 Mar 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=100 HOLLYWOOD, Fla., March 15, 2007 — News reporting prompts patient deaths when misleading “breakthroughs” are reported. Conversely, lack of media attention enables the all-but-silent shutdown of almost 100 clinical trials because of budget cuts at the National Institutes of Health. These two self-criticisms – and others – sprang up from a rare, candid look at how journalists cover cancer in a roundtable at the National Comprehensive Cancer Network’s 12th Annual Conference. Sam Donaldson, moderati... Thu, 15 Mar 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=99 JENKINTOWN, Pa., March 7, 2007 — Nearly 1,300 oncologists and cancer professionals have registered to attend the NCCN 12th Annual Conference: Clinical Practice Guidelines in OncologyandQuality Cancer Care taking place March 14 – 18, 2007 at the Westin Diplomat in Hollywood, Florida. The program includes the presentation of the NCCN Clinical Practice Guidelines in Oncology, updates from the NCCN PET/CT Imaging Task Force Report, and information about new cancer therapies and emerging issues in on... Wed, 7 Mar 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=98 JENKINTOWN, Pa., March 5, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. A significant issue the panel addressed was the results of a trial by Amgen, Inc. studying the use of Aranesp (darbepoetin alfa)... Mon, 5 Mar 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=96 JENKINTOWN, Pa., February 26, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Occult Primary Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. The 2007 version of the guidelines includes two new tables entitled Immunohistochemistry Markers for Unknown Primary Cancers for use in initial ... Mon, 26 Feb 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=97 JENKINTOWN, Pa., February 26, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. These guidelines are updated continually and are based upon evaluation of scientific data integrated with expert judgment. One o... Mon, 26 Feb 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=95 JENKINTOWN, Pa., February 21, 2007 — The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 of the world’s leading cancer centers, will present the Breast, Colorectal, Gastric, Non-Small Cell Lung and Non-Hodgkin`s Lymphoma (NHL) NCCN Clinical Practice Guidelines in Oncology in Beijing, Shanghai and Guangzhou, China. Over the course of five meetings in March and April, experts from NCCN Member Institutions and leading physicians in China will review and adapt these gui... Wed, 21 Feb 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=94 JENKINTOWN, Pa., February 13, 2007 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Breast Cancer Risk Reduction Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for care in oncology in both the community practice setting and in academic cancer centers. These guidelines are updated continually and are based upon evaluation of scientific data integrated with expert judgment. One major change in the 2... Tue, 13 Feb 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=90 JENKINTOWN, Pa., January 29, 2007 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Prostate Cancer Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for clinical care in oncology in both the community practice setting and in academic cancer centers. The panel of expert physicians from NCCN Member Institutions revised their recommendations regarding pelvic lymph node dissection. Robotic techniques are ... Mon, 29 Jan 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=91 JENKINTOWN, Pa., January 29, 2007 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Colon Cancer Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for clinical care in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are updated continually an... Mon, 29 Jan 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=92 JENKINTOWN, Pa., January 29, 2007 — The National Comprehensive Cancer Network (NCCN) is pleased to announce new updates to the NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer. These changes highlight leading developments in the treatment of non-small cell lung cancer and represent the recognized standard for clinical care in oncology in both the community and the academic practice settings. A significant issue the panel addressed was the data from the International ... Mon, 29 Jan 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=87 JENKINTOWN, Pa., January 8, 2007 —The National Comprehensive Cancer Network (NCCN) is pleased to announce updates to the NCCN Antiemesis Guidelines. The NCCN Clinical Practice Guidelines in Oncology are used extensively by managed care companies and by Medicare as the basis for coverage policies. The guidelines have a new recommendation for breakthrough treatment for chemotherapy-induced nausea/vomiting. Nabilone (Cesamet, Valeant) is now recommended for breakthrough treatment. The guideline... Mon, 8 Jan 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=88 Summary based on NCCN HER2 Testing Task Force Report JENKINTOWN, Pa., January 8, 2007 — The National Comprehensive Cancer Network (NCCN) and Research Advocacy Network have created an online report to educate breast cancer patients about the significance and importance of HER2 testing. Results of this test are essential in determining the correct treatment plan for breast cancer patients. Breast cancers can be categorized as HER2 positive or HER2 negative. HER2-positive breast cancer grows m... Mon, 8 Jan 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=89 JENKINTOWN, Pa., January 8, 2007 — The National Comprehensive Cancer Network (NCCN) is pleased to announce several new updates to the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes highlight leading developments in the treatment of multiple myeloma and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings. Assessing the response to treatment is a key determinant of myeloma treatment. The guid... Mon, 8 Jan 2007 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=86 JENKINTOWN, Pa., December 19, 2006 — The National Comprehensive Cancer Network (NCCN) DrugsandBiologics Compendium now includes an online tool to improve and optimize user searches. Cancer case managers, managed care decision-makers and other health care professionals will now be able to explore the compendium database more easily and quickly. Based on the NCCN Clinical Practice Guidelines in Oncology, the compendium delineates uses of drugs and biologics in the care of cancer patients, listi... Tue, 19 Dec 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=84 JENKINTOWN, Pa., December 13, 2006 — The National Comprehensive Cancer Network (NCCN) is proud to announce a new collaboration with Medscape from WebMD, the leading provider of online medical information and education for physicians and other healthcare professionals. The latest version of the NCCN Breast Cancer Guidelines, NCCN Clinical Practice in Oncology, will be published on Medscape at www.medscape.com/viewarticle/548868, bringing the recognized standard for clinical policy in the oncology... Wed, 13 Dec 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=85 Significant new treatments added JENKINTOWN, Pa., December 13, 2006 — The National Comprehensive Cancer Network (NCCN) is proud to announce several new updates to the NCCN Clinical Practice Guidelines in Oncology™ for Breast Cancer. These changes highlight leading developments in the treatment of breast cancer and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings. Based on results from the NSABP Study of Tamoxifen an... Wed, 13 Dec 2006 00:00 GMT http://www.nccn.org/professionals/meetings/12thannual/agenda.asp ... Tue, 14 Nov 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=173 Although there are now safe and effective ways to prevent and to treat predictable cases, like those involving pregnant women and cancer patients, many people who could benefit fail to receive adequate treatment, if any treatment at all. Common in Pregnancy In the 1960`s, a friend of mine spent her two pregnancies nauseated and vomiting. By the time her sons were born, she looked like a poorly nourished scarecrow. Fortunately, both babies, true to their role as parasites, were hale and hea... Tue, 24 Oct 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=82 Significant new treatment added JENKINTOWN, Pa., October 3, 2006 — The National Comprehensive Cancer Network (NCCN) is proud to announce several new updates to the NCCN Clinical Practice Guidelines in Oncology TM for Chronic Myelogenous Leukemia (CML). These changes highlight leading developments in the treatment of CML and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings. A panel of world-renowned experts added Dasatinib ... Tue, 3 Oct 2006 00:00 GMT http://www.nccn.org/about/publications/pdf/Your_Breast_Cancer_SURVIVAL_Guide.pdf ... Sun, 1 Oct 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=80 Internationally known faculty to share advances in the treatment of blood cancers. JENKINTOWN, Pa., September 5, 2006 — The National Comprehensive Cancer Network (NCCN) will debut a new educational program on September 8: the 1st Annual NCCN Hematologic Malignancies Congress. The event will be held at the Crown Plaza Times Square in New York. Over 100,000 new cases of hematologic malignancies will be diagnosed in 2006 alone. Important new treatment advances for these diseases have been introduc... Tue, 5 Sep 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=81 Funding will support innovative cancer research JENKINTOWN, Pa., September 5, 2006 — The National Comprehensive Cancer Network (NCCN) and Pfizer, Inc., have entered into a collaboration to conduct research on the oral multikinase inhibitor sunitinib (Sutent), a drug currently approved for advanced renal cell carcinoma and gastrointestinal stromal tumors. Sutent is being studied in a broad range of solid tumors. “NCCN’s goal is to improve the quality, effectiveness and efficiency of oncology prac... Tue, 5 Sep 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=79 Alexandria, VA – The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have collaborated to develop seven evidence-based quality measures for breast and colorectal cancers. The ASCO/NCCN Quality Measures can be applied to assess the extent to which oncologists are providing quality care to their patients. The measures and their specifications are available online at www.asco.org/qualitymeasures and www.nccn.org. The ASCO/NCCN Quality Measures are a... Mon, 14 Aug 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=78 Peer-reviewed oncology journal now a part of several bibliographic databases JENKINTOWN, Pa., August 11, 2006 — The NCCN is proud to announce that the JNCCN (Journal of the National Comprehensive Cancer Network) is now indexed in Elsevier’s Bibliographic Databases, a leading global indexing service that includes EMBASE, EMCare and Scopus. With inclusion in these additional bibliographic databases, JNCCN articles are more readily available to physicians, nurses, allied health professionals and ... Fri, 11 Aug 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=77 Latest results show JNCCN moving up among top oncology journals JENKINTOWN, Pa., July 24, 2006 — The Journal of the National Comprehensive Cancer Network (JNCCN) has increased its ranking among top oncology journals, according to FOCUS—a company that measures readership for medical journals. JNCCN, a monthly, peer-reviewed oncology publication, moved from ninth to eighth in readership, a quality determined by FOCUS based on reader survey responses. Twice a year, the company polls physicians to f... Mon, 24 Jul 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=76 Recommends NCCN’s Drugs and Biologics Compendium to CMS as Resource for Off-Label Anti-Cancer Therapy JENKINTOWN, Pa., July 18, 2006 — The American Society of Clinical Oncology (ASCO), the world’s leading professional organization representing physicians of all oncology subspecialties who care for people with cancer, has asked the Centers for Medicare and Medicaid Services (CMS) to recognize the NCCN Drugs and Biologics Compendium as one of the publications used for Medicare coverage of drugs us... Tue, 18 Jul 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=71 JENKINTOWN, Pa., May 10, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are ... Wed, 10 May 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=72 JENKINTOWN, Pa., May 10, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Soft Tissue Sarcoma Guidelines. The NCCN Clinical Practice Guidelines in Oncology™ are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are updated continua... Wed, 10 May 2006 00:00 GMT http://www.nccn.org/about/publications/pdf/Susman-NCCN-CMSDemoProject-May102006.pdf ... Wed, 10 May 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=70 JENKINTOWN, Pa., April 13, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Pancreatic Adenocarcinoma Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are updated c... Thu, 13 Apr 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=69 JENKINTOWN, Pa., April 4, 2006 — The National Comprehensive Cancer Network (NCCN) today announces the release of the new NCCN Venous Thromboembolic (VTE) Disease Guidelines. These guidelines outline the diagnosis, treatment and prevention of VTE—a potentially serious condition that occurs when a blood clot forms in the deep veins of the legs or in the pelvic veins. Cancer patients are especially at risk for VTE, which can result in serious complications like pulmonary embolism if not diagnosed a... Tue, 4 Apr 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=68 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine Joins National Comprehensive Cancer Network JENKINTOWN, Pa., March 15, 2006 — The National Comprehensive Cancer Network (NCCN), an alliance of the world’s leading cancer centers, is pleased to introduce a new member institution—the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri. With this addition, NCCN now includes 20 centers dedicated... Wed, 15 Mar 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=67 JENKINTOWN, Pa., March 7, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Kidney Cancer Guidelines. The NCCN Clinical Practice Guidelines in Oncology™ are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are updated continually a... Tue, 7 Mar 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=66 JENKINTOWN, Pa., March 6, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Ovarian Cancer Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are updated continually a... Mon, 6 Mar 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=65 JENKINTOWN, Pa., February 23, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are ... Thu, 23 Feb 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=64 JENKINTOWN, Pa., February 7, 2006 — With significant advances in cancer research and care, what can the medical community, patients and healthcare payors expect now and anticipate in the future? A prestigious panel of oncology and health care leaders will discuss the latest cancer advances at the National Comprehensive Cancer Network (NCCN) 11th Annual Conference: Clinical Practice GuidelinesandQuality Cancer Care on March 8-12, 2006, at The Westin Diplomat in Hollywood, Fla. The conference a... Tue, 7 Feb 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=61 JENKINTOWN, Pa., January 27, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Non-Hodgkin’s Lymphoma (NHL), Hodgkin Disease/Lymphoma, Head and Neck Cancers and Gastric and Esophageal Cancers Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care com... Fri, 27 Jan 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=62 JENKINTOWN, Pa., January 27, 2006 — The National Comprehensive Cancer Network (NCCN) has released specially coded versions of 13 NCCN Guidelines to support the 2006 Centers for Medicare and Medicaid Services (CMS) Oncology Demonstration Program. These NCCN Clinical Practice Guidelines in OncologyTM have been annotated with G-Codes from CMS and are available on www.nccn.org. The 2006 CMS Oncology Demonstration Program encourages high-quality care in all facets of the management of patients with ... Fri, 27 Jan 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=63 JENKINTOWN, Pa., January 27, 2005 — The National Comprehensive Cancer Network (NCCN) announces that Christopher E. Desch, M.D., has joined the NCCN as its National Medical Director. In this role, Dr. Desch will assume responsibility as the clinical leader for the broad spectrum of NCCN programs, including the NCCN Clinical Practice Guidelines in OncologyTM. Dr. Desch will work within the NCCN and with other national organizations to establish and enhance processes for the evaluation and improvem... Fri, 27 Jan 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=171 By MARILYNN MARCHIONE The Associated Press SAN ANTONIO — For years, doctors have known exactly what to do with breast cancer patients like Eva Ossorio: Poison them. Blasting women with toxic chemicals was considered the best way to save their lives. The bigger the cancer or the more it had spread, the more vile liquid doctors pumped into their veins to try to kill it. But there has been a sea change in the last year. Guidelines recently adopted in Europe and similar ones unveiled ... Sun, 11 Dec 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=60 JENKINTOWN, Pa., December 6, 2005 — The National Comprehensive Cancer Network (NCCN) is proud to offer two new tools in the fight against breast cancer: the latest version of the NCCN Breast Cancer Clinical Practice Guidelines and the Breast Cancer chapter of the NCCN DrugsandBiologics Compendium. These resources highlight cutting-edge developments in the treatment of breast cancer and represent the recognized standard for clinical policy in oncology in both community and academic practice setti... Tue, 6 Dec 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=59 Featured sessions include oncology leaders’ roundtable, Cancer Care in the 21st Century — RealityandPromise, moderated by Sam Donaldson JENKINTOWN, Pa., October 25, 2005 — An all-star panel of oncology and health care leaders discussing coming advances and improvements in cancer care is but one attraction of the National Comprehensive Cancer Network (NCCN) 11th Annual Conference: Clinical Practice GuidelinesandQuality Cancer Care. Scheduled for March 8-12, 2006, at The Westin Diplomat in Hol... Tue, 29 Nov 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=58 JENKINTOWN, Pa., November 8, 2005 — The Centers for Medicare and Medicaid Services (CMS) has announced that the Medicare Quality in Cancer Care Demonstration Project for 2006 will seek to improve the quality of care through reimbursement that fosters evidence-based practice. The Demonstration project will reimburse physicians who report whether their treatment of patients adheres to recommendations in nationally recognized practice guidelines published by either the National Comprehensive Cancer... Tue, 8 Nov 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=57 JENKINTOWN, Pa., October 31, 2005 — The National Comprehensive Cancer Network (NCCN) announced that it has entered into a collaboration with Roche Laboratories, Inc. to develop and review ongoing oncology research protocols and trials examining Xeloda (capecitabine) in combination with radiologic therapy, and other drugs and biologics in the treatment of solid tumors including esophageal, gastric and pancreatic cancers. “NCCN’s mission is to improve cancer care by studying and evaluating new a... Mon, 31 Oct 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=56 Recent updates for leukemia and bone cancer also posted on www.nccn.org JENKINTOWN, Pa., October 27, 2005 — The National Comprehensive Cancer Network (NCCN) announces the release of newly updated NCCN Clinical Practice Guidelines in Oncology for non-small cell lung cancer (NSCLC). Notable changes in NCCN’s updated NSCLC guidelines are the inclusion of bevacizumab (Genentech’s Avastin) plus chemotherapy as first-line treatment for advanced NSCLC, as well as newly defined principles of patholo... Thu, 27 Oct 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=55 JENKINTOWN, PA, October 11, 2005 — The National Comprehensive Cancer Network (NCCN), an alliance of 19 of the world’s leading cancer centers and the authoritative source of information about cancer care for patients and clinicians, and Univision Communications Inc. (NYSE:UVN), the nation’s leading Spanish-language media company, today announced a collaboration aimed at raising awareness of cancer risks, prevention, treatments, and clinical trials among Hispanics. Univision’s ongoing campaign is... Tue, 11 Oct 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=54 JENKINTOWN, Pa., September 13, 2005 — The National Comprehensive Cancer Network (NCCN) announces important new additions to the NCCN DrugsandBiologics Compendium, an authoritative source of evaluative information on the appropriate use of drugs and biologics in cancer care. NCCN has added the following titles to the list of available Compendium chapters: Kidney Cancer Testicular Cancer Non-Small Cell Lung Cancer Small Cell Lung Cancer Cancer- and Treatment-Related Anemia My... Tue, 13 Sep 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=53 Accredited Presentations Available to Oncology Professionals JENKINTOWN, Pa., August 9, 2005 — The National Comprehensive Cancer Network (NCCN) announced that CE-accredited presentations are now available online and on CD-ROM for oncology professionals. The presentations feature talks from NCCN experts recorded at regional guidelines symposia and the NCCN 10th Annual Conference: Clinical Practice GuidelinesandOutcomes Data in Oncology. “NCCN is pleased to provide valuable information about a... Tue, 9 Aug 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=52 JENKINTOWN, Pa., August 8, 2005 — The National Comprehensive Cancer Network (NCCN), in collaboration with the Multiple Myeloma Research Foundation (MMRF), has launched the Multiple Myeloma Resource Line. This free service provides physicians access to NCCN expert faculty, who answer questions on specific clinical issues related to the management of multiple myeloma. Physicians can call 866-528-NCCN (6226) Monday through Friday, 9 a.m. to 5 p.m. ET or e-mail questions to MultipleMyeloma@nccn.org.... Mon, 8 Aug 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=51 JENKINTOWN, Pa., June 13, 2005 — William T. McGivney, Ph.D., CEO of the National Comprehensive Cancer Network (NCCN), announces that Diane E. Paul, MS, RN, has joined NCCN as Vice President, Clinical Trials Network. In this role, Paul will be responsible for developing a centralized, standardized infrastructure for the conduct of clinical trials among NCCN’s 19 member institutions. “This network will be of interest to pharmaceutical/biotechnology companies for the conduct of their trials. And... Mon, 13 Jun 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=50 JENKINTOWN, PA — The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announces the release of its new Myeloid Growth Factors Guidelines outlining recommendations for prevention of cancer therapy-associated neutropenia. Neutropenia, reduction in white blood cells, is the major dose-limiting toxicity associated with chemotherapy which can lead to dose reductions, treatment delays, and poorer outcomes. The NCCN Myeloid Growth Factors... Tue, 19 Apr 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=48 JENKINTOWN, PA — The National Comprehensive Cancer Network (NCCN) announces the release of Chapters 4 and 5 of the NCCN DrugsandBiologics Compendium: Acute Myeloid Leukemia and Chronic Myelogenous Leukemia. “The NCCN DrugsandBiologics Compendium contains authoritative and definitive information about the appropriate use of drugs and biologics in the care of patients with leukemia – information that decision-makers at insurance and managed care companies and pharmacy benefits managers can use t... Mon, 28 Feb 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=49 JENKINTOWN, PA — The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announces that the NCCN Non-Small Cell Lung Cancer Guideline has recently been updated to broaden the options for treatment of advanced disease. NCCN’s panel of oncology experts added pemetrexed (Alimta, Eli Lilly and Company) as an option for second-line therapy for lung cancer. The panel indicated that it has been shown to be equivalent to docetaxel (Taxotere, San... Mon, 28 Feb 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=46 JENKINTOWN, PA, January 18, 2005 – William T. McGivney, Ph.D., CEO of the National Comprehensive Cancer Network (NCCN), announces that Patricia J. Goldsmith has joined NCCN as senior vice president for business development, public affairs and policy. McGivney stated that Goldsmith`s responsibilities will include establishing relationships with employers, employer groups, managed care companies and other national organizations. In addition, she will work to enhance the visibility of NCCN progra... Tue, 18 Jan 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=47 Distress Treatment Guidelines for Patients Improves Communication with Doctors and Enhances Cancer Treatment JENKINTOWN, PA, (January 11, 2005)- Distress Treatment Guidelines for Patients offers relief for a neglected area of cancer care: the emotional turmoil caused by the diagnosis, symptoms and treatment of cancer. Distress-a mix of anxiety and depressive symptoms-may cause sleeplessness, lack of appetite, trouble concentrating and difficulty carrying on regular activities. Although some dis... Tue, 11 Jan 2005 00:00 GMT http://webreprints.djreprints.com/1147811389503.html ... Tue, 11 Jan 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=45 Information About Appropriate Use of Drugs and Biologics in Treating Colon, Rectal, and Anal Cancers Now Available JENKINTOWN, PA, November 29, 2004 — The National Comprehensive Cancer Network announces an important new publication and authoritative source of information to guide the selection of appropriate treatment for patients. The first three chapters of the NCCN DrugsandBiologics Compendium have been recently released and focus on the appropriate use of drugs and biologics in colon, re... Mon, 29 Nov 2004 00:00 GMT http://www.communityoncology.net/journal/articles/0102098.pdf ... Thu, 18 Nov 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=44 The National Comprehensive Cancer Network (NCCN) won Honorable Mention — Best Use of Direct Marketing to Healthcare Professionals, at the first annual Medical MarketingandMedia Awards, in New York City on October 20, 2004. The award recognizes NCCN’s direct mail campaign, targeted to physicians and other oncology care providers, to promote the NCCN 9th Annual Conference: Clinical Practice GuidelinesandOutcomes Data in Oncology, held in Hollywood, Florida last March. Featuring direct mail piece... Thu, 28 Oct 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=42 JENKINTOWN, PA, August 2, 2004 - The National Comprehensive Cancer Network announces an important new publication and source of information to guide the selection of appropriate treatment for patients. The first edition of the NCCN Drugs and Biologics Compendium will be available on October 1, 2004. “A variety of constituencies in the health care community look to NCCN for evaluative information to aid their decision-making. NCCN again is responding to these needs by providing evaluative data... Mon, 2 Aug 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=41 JENKINTOWN, PA, April 20, 2004 – The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announces an update of the NCCN Colorectal Clinical Practice Guidelines. NCCN’s Colon, Rectal, and Anal Cancer panel met recently to discuss incorporation of two newly approved agents into treatment regimens for advanced colon and rectal cancer and to modify recommendations for adjuvant therapy for node positive colon cancer. Major changes include: ... Tue, 20 Apr 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=3 JENKINTOWN, PA, April 7, 2004 – On March 11, 2004, the National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announced a major update of the NCCN Antiemesis Clinical Practice Guidelines. The NCCN Antiemesis panel recently updated its guidelines for preventing chemotherapy-induced nausea and vomiting to add the 5-HT3 receptor antagonist palonosetron (Aloxi, MGI Pharma Inc.) to multiagent antiemetic regimens for use with highly and moder... Wed, 7 Apr 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=2 JENKINTOWN, PA, April 5, 2004 – The National Comprehensive Cancer Network (NCCN) and the American Cancer Society collaborated to update Nausea and Vomiting Treatment Guidelines for Patients with Cancer. This title is just one of a series, available in booklet form or online (www.nccn.org), that is dedicated to educating patients and their families about the treatment of cancer and associated side effects. “The nausea and vomiting which may be associated with cancer and its treatments can, a... Mon, 5 Apr 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=1 JENKINTOWN, PA, March 24, 2004 – On March 12, 2004, Stephen B. Edge, MD, FACS was elected to the Executive Committee of the Board of Directors of the National Comprehensive Cancer Network (NCCN), an alliance of 19 of the world’s leading cancer centers. This committee serves the NCCN Board in directing strategic, programmatic, and policy initiatives. “I am honored by the trust and responsibility of this appointment to the Executive Committee of the National Comprehensive Cancer Network, one of t... Wed, 24 Mar 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=4 JENKINTOWN, PA, March 17, 2004 – On March 12, 2004, David C. Hohn, MD was elected Chairman of the Board of Directors of the National Comprehensive Cancer Network (NCCN), an alliance of 19 of the world’s leading cancer centers. As the Chairman of the NCCN Board, Dr. Hohn will be responsible for enhancing the NCCN’s position as an active leader in responding to the issues and challenges facing our nation’s health care delivery system. “It is a great honor to be elected chairman of the board of th... Wed, 17 Mar 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=5 Hollywood, FL, March 11, 2004 – The National Comprehensive Cancer Network (NCCN) today introduces The NCCN Gastrointestinal Stromal Tumors (GIST) Task Force Report. The report, an expansion on The NCCN Sarcoma Clinical Practice Guidelines in Oncology, outlines the current thinking about the optimal management of patients with GIST. Though an uncommon cancer, GIST is increasingly recognized after experts reported that imatinib (Gleevec, Novartis Pharmaceuticals) an oral cancer therapy which tar... Thu, 11 Mar 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=7 JENKINTOWN, PA, March 8, 2004 – The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announces a major update of the NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines. In a significant addition to be presented on March 11 at the NCCN 9th Annual Conference: Clinical Practice GuidelinesandOutcomes Data in Oncology, the recently approved targeted therapy, gefitinib (Iressa, AstraZeneca Pharmaceuticals LP) is now recommended as ... Mon, 8 Mar 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=8 JENKINTOWN, PA, February 23, 2004 – The National Comprehensive Cancer Network (NCCN), an alliance of 19 of the world`s leading cancer centers, is pleased to announce the promotion of two of its top executives, Alana L. K. Brody and Joan S. McClure. Ms. Brody has been named Vice President, Business Development. In this position, she will lead NCCN`s relationships with the pharmaceutical and biotechnology industries, as well as oversee NCCN`s expansion of educational symposia and all r... Mon, 23 Feb 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=9 Free Service to Answer Patient-Oriented Questions JENKINTOWN, PA, January 30, 2004 – The National Comprehensive Cancer Network (NCCN) is pleased to announce the new NCCN Leukemia Resource Line. Physicians seeking guidance from leading leukemia experts can now call 1-888-469-NCCN (6226) to get feedback on diagnosing and treating leukemia patients. “NCCN is proud to be able to offer this new level of interaction to help support clinical decision-making and advance patient care,” sai... Fri, 30 Jan 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=10 Free Guide Aids Treatment Decision-Making JENKINTOWN, PA, January 6, 2004 – The National Comprehensive Cancer Network (NCCN) and the American Cancer Society today announce a new booklet designed to help educate patients and their families about non-Hodgkin’s lymphoma. Non-Hodgkin’s Lymphoma Treatment Guidelines for Patients is just one title in a series, available free in booklet form or online (www.nccn.org). Non-Hodgkin’s lymphoma is a cancer that begins in the lymphoid tissue, the... Tue, 6 Jan 2004 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=11 JENKINTOWN, PA, November 18, 2003 – The National Comprehensive Cancer Network, an alliance of nineteen of the world’s leading cancer centers, announces an update of the NCCN Breast Cancer Clinical Practice Guidelines. In a significant change, the NCCN’s Breast Cancer panel has added a new footnote to its recommendations for adjuvant therapy following primary therapy for breast cancer. Based on the recently closed MA-17 trial, panel members indicated that consideration of use of letrozole (F... Tue, 18 Nov 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=167 [1800] Utilization of Rituximab Therapy in Patients (pts) with Newly Diagnosed Follicular (FL) and Diffuse Large B Cell (DLCL) Non-Hodgkins Lymphoma (NHL) in the United States: An Analysis from the National Comprehensive Cancer Network (NCCN) [abstract]. NHL Outcomes Project [abstract]. American Society of Hematology: Session Type: Poster Session 912-I Jonathan W. Friedberg, Eva Lepisto, Maria Alma Rodriguez, Rebecca Ottensen, Ann S. LaCasce, Auayporn P. Nademanee, Michael Millenson, Myro... Sun, 16 Nov 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=12 NCCN Oncology Outcomes Database used in sentinel node biopsy study JENKINTOWN, PA, October 28, 2003 – A study published in the October 15 issue of the Journal of the National Cancer Institute suggests that sentinel node biopsy is emerging as the standard of care in the five major comprehensive cancer centers that participated in the study. If such acceptance occurs more broadly, say the authors, it may impact clinical trials currently underway. Researchers from five participating Nation... Tue, 28 Oct 2003 00:00 GMT http://jncicancerspectrum.oupjournals.org/cgi/content/abstract/jnci;95/20/1514 ... Wed, 15 Oct 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=14 JENKINTOWN, PA, September 8, 2003 – The National Comprehensive Cancer Network, an alliance of nineteen of the world’s leading cancer centers, announces an update of the NCCN Multiple Myeloma Clinical Practice Guidelines. The NCCN’s panel of oncology experts has added bortezomib (Velcade; Millennium Pharmaceuticals, Inc., Cambridge, MA) to its listing of chemotherapeutic agents that are considered appropriate for patients with progressive or refractory multiple myeloma who have previously been tr... Mon, 8 Sep 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=158 SUDBURY, MA, August 6, 2003 – JNCCN, the newly-launched journal of the National Comprehensive Cancer Network (NCCN), was recently presented with the APEX Award for Publication Excellence in the New Magazines and Journals subcategory of the Journals division. Clayton Jones, CEO of Jones and Bartlett, said, “This award recognizes the outstanding achievement that publication of the JNCCN represents, both in terms of scholarly publishing in general, and the NCCN’s pre-eminent role in the ... Wed, 6 Aug 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=15 ROCKLEDGE, PA, July 21, 2003 – The National Comprehensive Cancer Network (NCCN), an alliance of 19 of the world's leading cancer centers, is pleased to announce its newest CD-ROM, entitled Cancer Testing: Work up, Staging, and Follow-up within the Complete Library of NCCN Clinical Practice Guidelines in Oncology. The purpose of this CD-ROM is to serve as a resource to primary care physicians and specialists in areas other than oncology as they provide care to the patient with cancer. The c... Mon, 21 Jul 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=16 ROCKLEDGE, PA, June 23, 2003 – The Patient Advocate Foundation (www.patientadvocate.org) recently awarded William T. McGivney, PhD their National Humanitarian Healthcare Award, in recognition of his outstanding leadership and steadfast commitment to improving patient access to quality healthcare. Patient Advocate Foundation is a national non-profit organization that serves as an active liaison between the patient and their insurer, employer and/or creditors to resolve insurance, job retentio... Mon, 23 Jun 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=19 ROCKLEDGE, PA, March 3, 2003 – The National Comprehensive Cancer Network (NCCN) and the American Cancer Society are pleased to announce three new resources available to Spanish-speaking patients and their families. Ovarian Cancer, Melanoma, and Fever and Neutropenia are the newest additions to the Treatment Guidelines for Patients with Cancer series in the Spanish language. Other Spanish titles include Breast Cancer, Colon and Rectal Cancer, Lung Cancer, Prostate Cancer, Cancer Pain, Nausea an... Mon, 3 Mar 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=20 ROCKLEDGE, PA, February 20, 2003 - The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, is very pleased to announce the awarding of $1,886,237 in research grants provided through the NCCN Clinical Trials Network (CTN). “NCCN’s Clinical Trials Network, a program devoted to facilitating the development of promising new therapeutics to improve patient outcomes, is very pleased to offer research funding to support investigator-initiated... Thu, 20 Feb 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=21 ROCKLEDGE, PA, February 4, 2003 - The National Comprehensive Cancer Network (NCCN) announces the publication of the first of the 2003 NCCN Clinical Practice Guidelines in Oncology, the Colon and Rectal Cancer Treatment Guidelines, in the January edition of JNCCN, the official journal of the NCCN. These updated guidelines contain new treatment recommendations regarding the use of the recently approved agent, oxaliplatin, and of radiation therapy in Stage II, III, and IV disease. “The inclusi... Tue, 4 Feb 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=22 ROCKLEDGE, PA, February 3, 2003 - The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, proudly introduces the inaugural issue of The Journal of the National Comprehensive Cancer Network (JNCCN). JNCCN is published for the NCCN by Jones and Bartlett Publishers. A quarterly publication, JNCCN is one of the most widely circulated peer-reviewed journals in oncology. JNCCN focuses on communicating the NCCN Clinical Practice Guidelines ... Mon, 3 Feb 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=23 ROCKLEDGE, PA, January 27, 2003 – The National Comprehensive Cancer Network’s 8th Annual Conference: Clinical Practice GuidelinesandOutcomes Data in Oncology is being held on March 12 – 16, 2003 in Hollywood, Florida at the Westin Diplomat ResortandSpa. This annual meeting provides oncology professionals from across the country with a forum for discussing the newest updates of NCCN Clinical Practice Guidelines and Outcomes Data in Oncology. More than 700 oncologists (in both private prac... Mon, 27 Jan 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=24 ROCKLEDGE, PA, November 5, 2002 – The National Comprehensive Cancer Network (NCCN) today announced changes made to their Web site (www.nccn.org) which will allow physicians to more easily locate clinical trials. Physicians seeking new treatments for their patients with cancer often turn to clinical trials for answers. These research studies include trials testing new treatments, such as a new cancer drug or a new combination of drugs, new approaches to surgery or radiation therapy, or new ther... Tue, 5 Nov 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=26 ROCKLEDGE, PA, October 9, 2002 – The National Comprehensive Cancer Network (NCCN) is pleased to announce the NCCN Oncology Outcomes Database has achieved an exciting milestone by completing five years in operation. The most mature portion of this database — the breast cancer database — now collects, analyzes, and reports data on more than 10,000 women with breast cancer, providing researchers with valuable information to improve patient care. “The NCCN Oncology Outcomes Database has progre... Wed, 9 Oct 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=159 NCCN to study clinical applications of therapies in treatment of breast, gynecological, and other forms of cancer [PEAPACK, NJ] - Pharmacia Corporation today announced it has provided a $3.15 million grant to the National Comprehensive Cancer Network (NCCN) for the development and review of clinical oncology research protocols and trials in breast, gynecological and other forms of cancer. The grant will ... Mon, 26 Aug 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=160 Hartford Life is pleased to announce that Strategic Health Development Corporation and the National Comprehensive Cancer Network (NCCN) have teamed up to form the Strategic Health Cancer Network. This alliance will link our mutual clients` health plans to premier oncology facilities in the United States. Strategic Health has negotiated, on behalf of Hartford Life, favorable rates with select NCCN facilities ... Mon, 26 Aug 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=29 ROCKLEDGE, PA, August 22, 2002 – William T. McGivney, PhD, was recently elected vice president of the executive board of Patient Advocate Foundation (www.patientadvocate.org). Patient Advocate Foundation is a national non-profit organization that serves as an active liaison between the patient and their insurer, employer and/or creditors to resolve insurance, job retention and/or debt crisis matters relative to their diagnosis through case managers, doctors and attorneys. Patient Advocat... Thu, 22 Aug 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=30 Nineteen of the world`s leading cancer centers align to advance cancer treatment ROCKLEDGE, PA, June 5, 2002 - The National Comprehensive Cancer Network (NCCN) announces the launch of its Clinical Trials Network (CTN), a new strategy for advancing cancer therapies through clinical trials to improve patient care. A national, centralized infrastructure, CTN facilitates the initiation of clinical trials by ... Wed, 5 Jun 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=31 ... Mon, 20 May 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=33 HOLLYWOOD, FL - March 1, 2002 - Oncologists, oncology nurses, and patients now have a more comprehensive resource in their fight against breast cancer. The National Comprehensive Cancer Network (NCCN) presented the 2002 Breast Cancer Practice Guidelines at their 7th annual conference in Hollywood, Florida today. The NCCN Practice Guidelines in Oncology are the recognized standard for clinical policy in ... Fri, 1 Mar 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=34 ROCKLEDGE, PA, February 19, 2002 - Today the National Comprehensive Cancer Network (NCCN) announced that the NCCN Complete Library of Practice Guidelines in Oncology are now available through the Internet, as well as on CD-ROM. The NCCN Guidelines are recognized as the standard for clinical policy in oncology in the United States. "Creating the infrastructure to allow the NCCN Guidelines to be on t... Tue, 19 Feb 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=93 -- NCCN to study clinical applications of therapies in treatment of breast, gynecological, and other forms of cancer -- [PEAPACK, NJ] – Pharmacia Corporation today announced it has provided a $3.15 million grant to the National Comprehensive Cancer Network (NCCN) for the development and review of clinical oncology research protocols and trials in breast, gynecological and other forms of cancer. The grant will provide funding for clinical research to identify treatment advances that improve p... Tue, 1 Jan 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=161 By Mary Brophy Marcus Edith O’Neil-Page was once a cancer nurse, but even she had a hard time articulating her need for pain relief as she battled breast cancer three years ago. “Luckily, my husband saw when I needed something and either asked or encouraged me to ask,” says O’Neil-Page, 57, a director at Centinella Hospital and Medical Center in Inglewood, Calif. Now, a new tool for cancer patients and their families may help more of them speak up. A panel of cancer pain experts put t... Mon, 18 Jun 2001 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=35 Philadelphia, PA, May 17, 2001 – William P. Vaughan, MD, MBA, was recently elected Chairman of the Board of Directors for the National Comprehensive Cancer Network (NCCN). Dr. Vaughan is the Associate Director for Clinical Affairs and Director of the Bone Marrow Transplantation Program at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center. UAB is a member institution of the ... Thu, 17 May 2001 00:00 GMT http://www.cnn.com/2001/HEALTH/conditions/04/04/cancer.pain/index.html ... Wed, 4 Apr 2001 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=163 By Susan Brink “In the shower, you feel all soft, like a woman.” “I feel like my brain has been feminized.” “It’s like the male hysterectomy.” “It’s a delicate subject. There’s a virility issue.” “Your wife ain’t too happy.” “I was in the airport, nervous about flying and . . . whoosh. I lost control. Thank God I had clean clothes with me.” —Comments from prostate cancer survivors Prostate cancer is an inglorious disease, rife with indignities that cut to the core of male sexuality a... Mon, 22 May 2000 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=164 By Susan Brink Prostate cancer leaves little room for dignity. Charles Dixon, 57, lay belly up on the operating table, his head and feet lower than his gut. Split from his navel to the base of his penis, he is mercifully drugged into painless oblivion. Patrick Walsh, chairman of urology at Johns Hopkins Hospital, is carefully slicing free the walnut-size gland in what is called a nerve-sparing radical prostatectomy, designed to cure the cancer without interfering with sexual potency. “I... Mon, 3 Apr 2000 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=165 MINNEAPOLIS, MN, October 14, 1999 - Medtronic, Inc. (NYSE: MDT) and the National Comprehensive Cancer Network (NCCN) today announced that they are partnering in an effort to shed light on a key concern of cancer patients and their families: the best way to control cancer pain while preserving patients` quality of life. Medtronic will provide up to $525,000 in a three-year agreement to support the development and expansion of the NCCN Oncology Outcomes... Thu, 14 Oct 1999 00:00 GMT